Systemic lupus erythematosus (SLE) patients will suffer from some level of discomfort as the disease progresses due to involvement with the respiratory system. Shrinking lung syndrome is an uncommon disease side effect. SLE has traditionally been treated with chemical immunosuppressants. But these chemical drugs have low solubility, a short half-life in circulation, poor solubility, and higher side effects. One of the most effective ways to extend the time of circulation is to combine pharmaceuticals with nanocarriers that are developed. This method is particularly interesting autoimmune disorders have not been widely employed for the treatment of cancer and other infectious diseases. Here, we use a novel biocompatible polysaccharide nanoparticle, effectively synthesizing a simple but universal drug delivery platform. The immunosuppressant azathioprine was initially conjugated onto the polysaccharide nanocarrier in this proof-of-concept trial for the treatment of SLE. The kidneys only cleared the AZA-PHA nanoparticles slowly, and they had a 30% cytotoxicity. Azathioprine-polysaccharide nanoparticles demonstrated greater therapeutic efficacy to azathioprine-polysaccharide nanoparticles in a murine SLE model without significantly increasing toxicity. This delivery method, which might act as a fresh and universal platform, might make it possible to treat SLE.

系统性红斑狼疮 (SLE) 患者由于呼吸系统受累，随着疾病的进展，会出现一定程度的不适。肺萎缩综合症是一种罕见的疾病副作用。SLE 传统上采用化学免疫抑制剂治疗。但这些化学药物溶解度低、循环半衰期短、溶解度差、副作用较高。延长循环时间的最有效方法之一是将药物与已开发的纳米载体结合起来。这种方法尤其令人感兴趣的自身免疫性疾病尚未广泛用于治疗癌症和其他传染病。在这里，我们使用一种新型的生物相容性多糖纳米颗粒，有效地合成了一个简单但通用的药物输送平台。在这项用于治疗 SLE 的概念验证试验中，免疫抑制剂硫唑嘌呤最初被缀合到多糖纳米载体上。肾脏只能缓慢地清除 AZA-PHA 纳米颗粒，并且它们具有 30% 的细胞毒性。硫唑嘌呤-多糖纳米颗粒在小鼠 SLE 模型中表现出更高的治疗功效，且不会显着增加毒性。这种递送方法可能作为一个新颖且通用的平台，可能使治疗 SLE 成为可能。硫唑嘌呤-多糖纳米颗粒在小鼠 SLE 模型中表现出更高的治疗功效，且不会显着增加毒性。这种递送方法可能作为一个新颖且通用的平台，可能使治疗 SLE 成为可能。硫唑嘌呤-多糖纳米颗粒在小鼠 SLE 模型中表现出更高的治疗功效，且不会显着增加毒性。这种递送方法可能作为一个新颖且通用的平台，可能使治疗 SLE 成为可能。